Administration of the KCa channel activator SKA-31 improves endothelial function in the aorta of atherosclerosis-prone mice
Our data show that prolonged administration of the K<sub>Ca</sub> channel activator SKA-31 improved endothelial function without modifying fatty plaque formation in the aorta of Apoe<sup>-/-</sup> mice.
Authors
- Andrew P. Braun (ORCID: https://orcid.org/0000-0002-7739-5325)
- Heike Wulff (ORCID: https://orcid.org/0000-0003-4437-5763)
- Darrell D. Belke (ORCID: https://orcid.org/0009-0002-4418-7201)
- Rayan Khaddaj‐Mallat (ORCID: https://orcid.org/0000-0002-8850-6342)
- Liam Hamm
- O. Daniel Vera
- Yong-Xiang Chen (ORCID: https://orcid.org/0000-0002-8156-147X)
- Ramesh C. Mishra (ORCID: https://orcid.org/0000-0003-0190-8849)
- Latika Singh
- Barak Almarzouq
Institutions
- University of Calgary (CA)
- Libin Cardiovascular Institute of Alberta (CA)
- University of California, Davis (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-28
- DOI
- https://doi.org/10.3389/fphar.2025.1545050
- Primary Topic
- Nitric Oxide and Endothelin Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada